Aerosolized pentamidine failure rate
Is 13% on currently recommended dose schedule of 300 mg over four weeks for prophylaxis and treatment of HIV-related Pneumocystic carinii pneumonia, Henry Masur, chief of clinical medicine at NIH's Clinical Center, reported May 7. Longer term studies are showing 20-25% failure rates for the drug, Masur said.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.